OBJECTIVES: The goal of this meta-analysis was to determine if within the sodium- glucose cotransporter 2 (SGLT 2) inhibitors class, any individual drug increases the risk of urinary tract infection (UTI). METHODS: Data base search was conducted using Medline, PubMed, and Google Scholar. Study included trials of FDA approved SGLT 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. To ensure internal validity of the selected studies, only randomized controlled trials which included patients with diabetes were included. Any trials with any special groups of patients, for example, patients with cardiovascular disease were excluded. Non-randomized trials, case reports, editorials, letters to the editors, and studies with no comparison group were excluded. Trials which did not report UTI as a side effect were excluded. A meta-analysis was conducted and data was pooled using odds ratio and 95% confidence intervals. All analysis was performed using SAS version 9.4. RESULTS: When the three drugs were compared, there was no significant difference in odds of developing a UTI. Sensitivity analyses were performed by excluding, in turn, the contribution of each study to the meta-analysis data. There was no significant difference in the results. CONCLUSIONS: Although the study reinforced the finding that urinary tract infection is one of the major adverse events caused by this class of antidiabetic drugs, this meta-analysis suggested that there was no significant difference in risk of UTIs among the three SGLT 2 inhibitors on the market.